CSBR - Champions Oncology, Inc.
| Previous Close | 7.51 |
| Open | 7.55 |
| Bid | 7.89 x 1300 |
| Ask | 10.00 x 3200 |
| Day's Range | 7.51 - 7.99 |
| 52 Week Range | 3.80 - 17.90 |
| Volume | 63,061 |
| Avg. Volume | 61,843 |
| Market Cap | 91.761M |
| Beta (3Y Monthly) | 3.64 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.02 |
| Earnings Date | Mar 20, 2019 - Mar 25, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.33 |
- Zacks•2 days ago
Moving Average Crossover Alert: Champions Oncology
Champions Oncology, Inc. (CSBR) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
- Zacks•3 days ago
New Strong Sell Stocks for April 16th
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today
- Zacks•18 days ago
New Strong Sell Stocks for April 1st
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today
- Zacks•23 days ago
New Strong Sell Stocks for March 27th
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today:
- ACCESSWIRE•last month
Champions Oncology Reports Quarterly Revenue of $6.4 Million
Reiterates Expectations for Revenue Growth of at Least 20% for Fiscal Year 2019 HACKENSACK, NJ / ACCESSWIRE / March 18, 2019 / Champions Oncology, Inc. (NASDAQ: CSBR), engaged in an end-to-end range of ...
- ACCESSWIRE•last month
Champions Oncology to Announce Third Quarter Financial Results on Monday, March 18, 2019
HACKENSACK, NJ / ACCESSWIRE / March 6, 2019 / Champions Oncology, Inc. (NASDAQ: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development ...
- Zacks•last month
Champions Oncology (CSBR) Q3 Earnings: What's in Store?
During Champions Oncology's (CSBR) third-quarter fiscal 2019 conference call, investor focus will be on the company's progress with its Ex Vivo platform and services.
- Zacks•3 months ago
Weakness Seen in Champions Oncology (CSBR) Estimates: Should You Stay Away?
Champions Oncology (CSBR) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
- ACCESSWIRE•4 months ago
Champions Oncology Participates in Pre-Clinical Studies to Identify Novel Therapy for Childhood Cancer
HACKENSACK, NJ / ACCESSWIRE / December 17, 2018 / Champions Oncology, Inc. (CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced, in partnership with Drs. Narendra Bharathy and Charles Keller at the Children's Cancer Therapy Development Institute (cc-TDI), the publication of in-vivo oncology pharmacology data presenting the effectiveness of the investigational drug entinostat in Patient Derived Xenograft (PDX) models of Pediatric Rhabdomyosarcoma. The data, published in Science Signaling (http://stke.sciencemag.org/content/11/557/eaau7632.editor-summary) demonstrates the advantages of utilizing well-selected PDX models in pre-clinical drug development and helped confirm the earlier research performed by Drs. Bharathy and Keller at cc-TDI.
- ACCESSWIRE•4 months ago
Champions Oncology Reports Quarterly Revenue of $6.7 Million
Reiterates Expectations for Revenue Growth of at Least 20% for Fiscal Year 2019 HACKENSACK, NJ / ACCESSWIRE / December 17, 2018 / Champions Oncology, Inc. (NASDAQ: CSBR), engaged in an end-to-end range ...
- PR Newswire•4 months ago
Champions Oncology to Announce Second Quarter Financial Results on Monday, December 17, 2018
HACKENSACK, N.J., Dec. 10, 2018 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced it will report its financial and operational results for the second quarter ended October 31, 2018, on Monday, December 17, 2018. The company will host a conference call to discuss the second quarter results that day at 4:30 p.m. EST (1:30 p.m. PST). A replay of the call will be available by dialing 877-481-4010 or 919-882-2331 and entering Passcode: 41544, or by accessing the Investor tab of the company's website within 72 hours.
- Zacks•5 months ago
Champions Oncology (CSBR) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, Champions Oncology (CSBR) closed at $10.39, marking a +0.39% move from the previous day.
- GlobeNewswire•5 months ago
Analysis: Positioning to Benefit within Red Lion Hotels, P.A.M. Transportation Services, Champions Oncology, Kingstone Companies, Applied DNA Sciences, and Innodata — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Nov. 15, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- PR Newswire•5 months ago
Champions Oncology to Participate in the 9th Annual Craig-Hallum Alpha Select Conference
HACKENSACK, N.J., Nov. 7, 2018 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced that management, will participate in the 9th annual Craig-Hallum Alpha Select conference on Thursday, November 15, 2018, in New York. For more information about the conference or to schedule a one-on-one meeting with management, please contact your Craig Hallum representative or Hayden IR at james@haydenir.com. Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs.
- Zacks•6 months ago
Champions Oncology Sees Hammer Chart Pattern: Time to Buy?
Champions Oncology has been struggling lately, but the selling pressure may be coming to an end soon.
- Zacks•6 months ago
Has Champions Oncology (CSBR) Outpaced Other Medical Stocks This Year?
Is (CSBR) Outperforming Other Medical Stocks This Year?
- Zacks•6 months ago
Champions Oncology (CSBR) Gains As Market Dips: What You Should Know
Champions Oncology (CSBR) closed at $12.21 in the latest trading session, marking a +0.58% move from the prior day.
- Zacks•6 months ago
Bull Of The Day: Champions Oncology (CSBR)
Bull Of The Day: Champions Oncology (CSBR)
- Zacks•7 months ago
Best ETFs & Stocks From the Top Sector of Q3
Healthcare was the best-performing sector of the third quarter, jumping 14.1% - its highest quarterly gain since the first quarter of 2013.
- Zacks•7 months ago
Looking for a Top Momentum Pick? Why Champions Oncology (CSBR) is a Great Choice
Does Champions Oncology (CSBR) have what it takes to be a top stock pick for momentum investors? Let's find out.
- PR Newswire•7 months ago
Champions Oncology Reports Record Quarterly Revenue of $6.2 Million
Reiterates Expectations for Revenue Growth of at Least 20% for Fiscal Year 2019 HACKENSACK, N.J. , Sept. 13, 2018 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in an end-to-end range ...
- PR Newswire•7 months ago
Champions Oncology to Participate at the Janney Montgomery Scott Healthcare Conference 2018 in New York
HACKENSACK, N.J., Sept. 13, 2018 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced that management will participate at the Janney Montgomery Scott Healthcare Conference 2018 on Monday, September 17th in New York. To schedule a meeting, please contact your conference representative or James Carbonara at Hayden IR. Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs.
